Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Declines By 28.9%

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 421,900 shares, a drop of 28.9% from the October 15th total of 593,700 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily volume of 75,800 shares, the days-to-cover ratio is currently 5.6 days.

Anixa Biosciences Stock Down 1.0 %

ANIX stock traded down $0.03 during trading hours on Friday, hitting $3.10. 48,347 shares of the stock were exchanged, compared to its average volume of 109,327. Anixa Biosciences has a 12 month low of $2.14 and a 12 month high of $5.13. The company has a 50-day simple moving average of $3.27 and a two-hundred day simple moving average of $2.99.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. On average, equities analysts anticipate that Anixa Biosciences will post -0.42 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANIX shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, September 17th. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a report on Wednesday, August 7th.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently modified their holdings of the business. Concorde Asset Management LLC bought a new position in Anixa Biosciences during the 2nd quarter worth $31,000. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Anixa Biosciences by 50.0% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after buying an additional 7,500 shares in the last quarter. Virtu Financial LLC grew its stake in shares of Anixa Biosciences by 47.2% in the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares during the period. Tyler Stone Wealth Management raised its holdings in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the last quarter. Finally, International Assets Investment Management LLC grew its holdings in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.